{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:39:39Z","timestamp":1788489579248,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cardfail.2024.04.030","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T05:23:38Z","timestamp":1716701018000},"page":"1568-1577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association of Sacubitril\/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-7007","authenticated-orcid":false,"given":"MARAT","family":"FUDIM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEREK D.","family":"CYR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JONATHAN H.","family":"WARD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ADRIAN F.","family":"HERNANDEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SERGE","family":"LEPAGE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVID A.","family":"MORROW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAVITA","family":"SHARMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRIAN L.","family":"CLAGGETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RANDALL C.","family":"STARLING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ERIC J.","family":"VELAZQUEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KRISTIN M.","family":"WILLIAMSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AKSHAY S.","family":"DESAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHELLEY","family":"ZIEROTH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SCOTT D.","family":"SOLOMON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EUGENE","family":"BRAUNWALD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBERT J.","family":"MENTZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2024.04.030_bib0001","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0002","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0003","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0004","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2023.02.001","article-title":"Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril\/valsartan versus valsartan in HFmrEF and HFpEF with a worsening heart failure event","volume":"29","author":"Mentz","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0008","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ejhf.1050","article-title":"Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion","volume":"20","author":"Van Aelst","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2017.03.249","article-title":"Trajectory of congestion metrics by ejection fraction in patients with acute heart failure (from the Heart Failure Network)","volume":"120","author":"Ambrosy","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2016.09.012","article-title":"Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF Trial","volume":"5","author":"Ambrosy","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015752","article-title":"Ultrafiltration in acute heart failure: implications of ejection fraction and early response to treatment from CARRESS-HF","volume":"9","author":"Fudim","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0012","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/ehf2.13453","article-title":"Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction","volume":"8","author":"He","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0013","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jacc.2017.05.029","article-title":"Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0014","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ejheart.2007.06.003","article-title":"Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function","volume":"9","author":"Balmain","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jacc.2011.09.062","article-title":"Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy","volume":"59","author":"Schwartzenberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.030_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021584","article-title":"Comprehensive physiological modeling provides novel insights into heart failure with preserved ejection fraction physiology","volume":"10","author":"Kaye","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424001878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424001878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T11:07:41Z","timestamp":1733828861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916424001878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1071916424001878"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.030","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Sacubitril\/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}